Tumor Promotion in BRAF Wild-Type Tumors: In vitro experiments have demonstrated paradoxical activation of MAP-kinase signaling and increased cell proliferation in BRAF wild-type cells exposed to BRAF ...

An increasing number of people are dying of colorectal cancer at a young age. The death of actor James Van Der Beek, who was ...

Earlier in February 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

A research team investigating the use of the bacterium Listeria monocytogenes against colorectal cancer has discovered a way ...

Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...

Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a ...

Lunai Bioworks (NASDAQ: LNAI) has launched a new oncology collaboration with a clinical-stage partner to apply artificial intelligence to data from a randomized Phase 2 trial in metastatic colorectal ...

Metastatic Colorectal Cancer Market Global Assessment Report 2026 To 2035. February 17, 2026 11:36 pm - Global Metastatic Colorectal Cancer Market Size is valued at USD 7.68 Bn in 2025 and is ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly improved overall survival (OS) among previously treated patients with metastatic ...